| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1049145175 |
| P356 | DOI | 10.1007/S00223-013-9741-7 |
| P698 | PubMed publication ID | 23700149 |
| P2093 | author name string | T John Martin | |
| Kim Henriksen | |||
| Morten A Karsdal | |||
| P2860 | cites work | Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates | Q22010646 |
| Suppression of bone formation by osteoclastic expression of semaphorin 4D | Q24294299 | ||
| Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations | Q24310432 | ||
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 | ||
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling | Q24319108 | ||
| Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis | Q28140437 | ||
| Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis | Q28143618 | ||
| Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors | Q28145862 | ||
| 'Eph'ective signaling: forward, reverse and crosstalk | Q28179338 | ||
| The ephrins and Eph receptors in neural development | Q28266706 | ||
| Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis | Q28286738 | ||
| Plexin A is a neuronal semaphorin receptor that controls axon guidance | Q28292881 | ||
| Ephrin-B1 forward and reverse signaling are required during mouse development | Q28504499 | ||
| Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis | Q28510537 | ||
| Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis | Q28593488 | ||
| Dissociation of bone resorption and bone formation in adult mice with a non-functional V-ATPase in osteoclasts leads to increased bone strength | Q28743063 | ||
| Osteoclast differentiation and activation | Q29547556 | ||
| Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice | Q29547898 | ||
| Eph receptor signalling casts a wide net on cell behaviour | Q29619988 | ||
| A physical mechanism for coupling bone resorption and formation in adult human bone. | Q30485638 | ||
| Bone density, strength, and formation in adult cathepsin K (-/-) mice | Q33374935 | ||
| Osteoclasts control osteoblast chemotaxis via PDGF-BB/PDGF receptor beta signaling | Q33379619 | ||
| Ephrin B1 regulates bone marrow stromal cell differentiation and bone formation by influencing TAZ transactivation via complex formation with NHERF1. | Q33613966 | ||
| Advances in the osteoblast lineage | Q33678389 | ||
| Targeted disruption of ephrin B1 in cells of myeloid lineage increases osteoclast differentiation and bone resorption in mice | Q34189741 | ||
| Osteopetrosis | Q34380528 | ||
| A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss | Q34567407 | ||
| A new heterozygous mutation (R714C) of the osteopetrosis gene, pleckstrin homolog domain containing family M (with run domain) member 1 (PLEKHM1), impairs vesicular acidification and increases TRACP secretion in osteoclasts | Q34712790 | ||
| Tyrosine Phosphatase Epsilon Is a Positive Regulator of Osteoclast Function in Vitro and In Vivo | Q34786247 | ||
| EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts | Q34796085 | ||
| Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. | Q35083626 | ||
| Parathyroid hormone stimulates bone formation and resorption in organ culture: evidence for a coupling mechanism | Q35367510 | ||
| Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways | Q35632149 | ||
| Osteoclast-derived activity in the coupling of bone formation to resorption. | Q36032429 | ||
| Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border | Q36213974 | ||
| Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells | Q36223256 | ||
| Boning up on ephrin signaling | Q36562476 | ||
| Sphingosine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal cell migration through S1P activation of complementary kinase pathways | Q36636026 | ||
| Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-κB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity | Q36636031 | ||
| Are nonresorbing osteoclasts sources of bone anabolic activity? | Q36709511 | ||
| Semaphorin 3B is a 1,25-Dihydroxyvitamin D3-induced gene in osteoblasts that promotes osteoclastogenesis and induces osteopenia in mice | Q36710174 | ||
| Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton | Q36774955 | ||
| Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice | Q36791739 | ||
| The mature osteoblast phenotype is characterized by extensive plasticity | Q36859389 | ||
| Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. | Q36927212 | ||
| Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. | Q37015968 | ||
| EphA4 as an effector of Twist1 in the guidance of osteogenic precursor cells during calvarial bone growth and in craniosynostosis | Q37201448 | ||
| gp130 signaling in bone cell biology: multiple roles revealed by analysis of genetically altered mice. | Q37274809 | ||
| TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation | Q37307155 | ||
| Advances in osteoclast biology resulting from the study of osteopetrotic mutations. | Q37318849 | ||
| BMP-6 and mesenchymal stem cell differentiation | Q37630029 | ||
| Osteoclast Activity and Subtypes as a Function of Physiology and Pathology—Implications for Future Treatments of Osteoporosis | Q37790176 | ||
| Afamin secreted from nonresorbing osteoclasts acts as a chemokine for preosteoblasts via the Akt-signaling pathway | Q39322224 | ||
| A specific subtype of osteoclasts secretes factors inducing nodule formation by osteoblasts. | Q39327208 | ||
| The pathobiology of the osteoclast | Q39492910 | ||
| Control of skeletal patterning by ephrinB1-EphB interactions | Q39657563 | ||
| Skeletal renewal and metabolic bone disease | Q39890602 | ||
| Activation of p38 Mitogen-Activated Protein Kinase Is Required for Osteoblast Differentiation | Q40655078 | ||
| Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor | Q40754782 | ||
| Role of osteoblasts in hormonal control of bone resorption—A hypothesis | Q41551873 | ||
| Osteoprotection by semaphorin 3A. | Q41791623 | ||
| Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts | Q42520796 | ||
| Osteoclasts secrete non-bone derived signals that induce bone formation. | Q42819536 | ||
| Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). | Q44796989 | ||
| Increased presence of capillaries next to remodeling sites in adult human cancellous bone. | Q45881370 | ||
| Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling | Q46291802 | ||
| Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis | Q50335578 | ||
| Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. | Q54227754 | ||
| EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. | Q54470749 | ||
| Basic Principles of Bone Cell Biology | Q57265493 | ||
| Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization | Q57272396 | ||
| Premature loss of bone remodeling compartment canopies is associated with deficient bone formation: A study of healthy individuals and patients with cushing's syndrome | Q57566244 | ||
| Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis | Q57675131 | ||
| c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling | Q58326943 | ||
| Suggested Sequential Mode of Control of Changes in Cell Behaviour in Adult Bone Remodelling | Q59076842 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 88-97 | |
| P577 | publication date | 2013-05-23 | |
| P1433 | published in | Calcified Tissue International | Q5018771 |
| P1476 | title | Osteoclast-derived coupling factors in bone remodeling | |
| P478 | volume | 94 |
| Q99561826 | Bone Marrow Microvasculature |
| Q33794615 | Bone Size and Quality Regulation: Concerted Actions of mTOR in Mesenchymal Stromal Cells and Osteoclasts |
| Q40067017 | Cardiovascular risk assessment in osteoporotic patients using osteoprotegerin as a reliable predictive biochemical marker. |
| Q38579689 | Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis |
| Q38666521 | Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned |
| Q36110956 | Chitosan nanofiber scaffold improves bone healing via stimulating trabecular bone production due to upregulation of the Runx2/osteocalcin/alkaline phosphatase signaling pathway |
| Q90263630 | Coupling factors involved in preserving bone balance |
| Q37557163 | Decreased bone formation and increased osteoclastogenesis cause bone loss in mucolipidosis II. |
| Q91958357 | Deficiency of sphingosine-1-phosphate receptor 3 does not affect the skeletal phenotype of mice lacking sphingosine-1-phosphate lyase |
| Q36447553 | Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities |
| Q92341659 | Dose-dependent roles of aspirin and other non-steroidal anti-inflammatory drugs in abnormal bone remodeling and skeletal regeneration |
| Q52885465 | Early reversal cells in adult human bone remodeling: osteoblastic nature, catabolic functions and interactions with osteoclasts. |
| Q37652063 | Effect of aging on stem cells. |
| Q96950725 | Effect of echinalkamide identified from Echinacea purpurea (L.) Moench on the inhibition of osteoclastogenesis and bone resorption |
| Q53808499 | Effects of Long-Term Odanacatib Treatment on Bone Gene Expression in Ovariectomized Adult Rhesus Monkeys: Differentiation From Alendronate. |
| Q90407419 | Exosomes: mediators of bone diseases, protection, and therapeutics potential |
| Q61446362 | Extracellular vesicles in bone: "dogrobbers" in the "eternal battle field" |
| Q33761255 | Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues |
| Q90451142 | Friend or Foe? Essential Roles of Osteoclast in Maintaining Skeletal Health |
| Q26777956 | High Cholesterol Deteriorates Bone Health: New Insights into Molecular Mechanisms |
| Q64084531 | Immune Modulation by Transplanted Calcium Phosphate Biomaterials and Human Mesenchymal Stromal Cells in Bone Regeneration |
| Q51758043 | Involvement of serum-derived exosomes of elderly patients with bone loss in failure of bone remodeling via alteration of exosomal bone-related proteins. |
| Q88412429 | Local administration of WP9QY (W9) peptide promotes bone formation in a rat femur delayed-union model |
| Q64060632 | Membrane trafficking in osteoclasts and implications for osteoporosis |
| Q37071194 | Mesenchymal stem cell aging: Mechanisms and influences on skeletal and non-skeletal tissues |
| Q90388414 | Metformin protects bone mass in ultra-high-molecular-weight polyethylene particle-induced osteolysis by regulating osteocyte secretion |
| Q47220639 | MiR-30a attenuates osteoclastogenesis via targeting DC-STAMP-c-Fos-NFATc1 signaling |
| Q58572612 | Models of Bone Remodelling and Associated Disorders |
| Q27022580 | Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis |
| Q55261693 | Molecular mechanisms of glucocorticoids on skeleton and bone regeneration after fracture. |
| Q58595932 | NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma |
| Q36830353 | Naringin ameliorates bone loss induced by sciatic neurectomy and increases Semaphorin 3A expression in denervated bone |
| Q36047882 | Notch signaling promotes osteoclast maturation and resorptive activity. |
| Q38470745 | Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disorders |
| Q51765760 | Osteoclast-secreted SLIT3 coordinates bone resorption and formation. |
| Q52595611 | Osteoclasts degrade bone and cartilage knee joint compartments through different resorption processes. |
| Q34474147 | PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis |
| Q37351613 | PLEKHM1/DEF8/RAB7 complex regulates lysosome positioning and bone homeostasis. |
| Q39654548 | Peptide drugs accelerate BMP-2-induced calvarial bone regeneration and stimulate osteoblast differentiation through mTORC1 signaling |
| Q57976931 | Pharmacological inhibition of Dock5 prevents osteolysis by affecting osteoclast podosome organization while preserving bone formation |
| Q38306944 | RANKL/OPG; Critical role in bone physiology. |
| Q58776864 | Rab GTPases in Osteoclastic Endomembrane Systems |
| Q38849982 | Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice |
| Q93078435 | Supplementation with 45S5 Bioactive Glass Reduces In Vivo Resorption of the β-Tricalcium-Phosphate-Based Bone Substitute Material Vitoss |
| Q28546666 | The Crosstalk between Osteoclasts and Osteoblasts Is Dependent upon the Composition and Structure of Biphasic Calcium Phosphates |
| Q33920055 | The best of both worlds - managing the cancer, saving the bone |
| Q41989650 | The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study. |
| Q61443001 | The potential risks of C-C chemokine receptor 5-edited babies in bone development |
| Q38239680 | The reversal phase of the bone-remodeling cycle: cellular prerequisites for coupling resorption and formation |
| Q28073668 | The roles of bone-derived exosomes and exosomal microRNAs in regulating bone remodelling |
| Q42139802 | Ubiquitin E3 Ligase LNX2 is Critical for Osteoclastogenesis In Vitro by Regulating M-CSF/RANKL Signaling and Notch2. |
| Q38848770 | miR-218 is involved in the negative regulation of osteoclastogenesis and bone resorption by partial suppression of p38MAPK-c-Fos-NFATc1 signaling: Potential role for osteopenic diseases |
| Q36804980 | p38α MAPK Regulates Lineage Commitment and OPG Synthesis of Bone Marrow Stromal Cells to Prevent Bone Loss under Physiological and Pathological Conditions |
| Q37739585 | p38α MAPK regulates proliferation and differentiation of osteoclast progenitors and bone remodeling in an aging-dependent manner |
Search more.